Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418806 | 0.90 | SCN10A (0.53) | SCN10ATDP1KMT2ALMNATSHR | |
| SCHEMBL2420059 | 0.81 | SCN10A (0.54) | SCN10AKMT2ALMNATSHRNPSR1 | |
| SCHEMBL2415948 | 0.80 | SCN10A (0.54) | SCN10AKMT2ALMNATSHRNPSR1 | |
| SCHEMBL2418091 | 0.79 | SCN10A (0.53) | SCN10ATDP1KMT2ALMNATSHR | |
| SCHEMBL2416261 | 0.79 | SCN10A (0.75) | SCN10ALMNATSHRNPSR1SCN1A | |
| SCHEMBL2419090 | 0.79 | SCN10A (0.51) | SCN10AKMT2ALMNATSHRNPSR1 | |
| SCHEMBL2416063 | 0.78 | SCN10A (0.48) | SCN10AKMT2ALMNATSHRNPSR1 | |
| SCHEMBL2410050 | 0.77 | SCN10A (0.52) | SCN10AKMT2ASCN1ASCN5ASCN9A | |
| SCHEMBL2415208 | 0.77 | SCN10A (0.50) | SCN10AKMT2ALMNASCN1ASCN5A | |
| SCHEMBL2410516 | 0.76 | SCN10A (0.75) | SCN10AKMT2ALMNASCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | claimed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | claimed |
| EP-1945630-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | claimed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | claimed |
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1945630-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | P2RX5, P2RX3, AADAC | SCN10A 245/4885TDP1 3694/4885KMT2A 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.